Macquarie Group’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $22.8M | Hold |
120,191
| – | – | 0.1% | 174 |
|
|
2026
Q1 | $23.7M | Buy |
+120,191
| New | +$23.2M | 0.14% | 134 |
|
|
2025
Q4 | – | Sell |
-173,288
| Closed | -$26.6M | – | 922 |
|
|
2025
Q3 | $26.6M | Sell |
173,288
-10,932
| -6% | -$1.65M | 0.03% | 584 |
|
|
2025
Q2 | $25.7M | Sell |
184,220
-225
| -0.1% | -$31.5K | 0.03% | 598 |
|
|
2025
Q1 | $27.1M | Sell |
184,445
-72,619
| -28% | -$10.5M | 0.03% | 572 |
|
|
2024
Q4 | $33.7M | Sell |
257,064
-50,476
| -16% | -$7.07M | 0.04% | 523 |
|
|
2024
Q3 | $47.9M | Buy |
307,540
+98,784
| +47% | +$15.9M | 0.05% | 459 |
|
|
2024
Q2 | $32.6M | Sell |
208,756
-37,239
| -15% | -$5.6M | 0.04% | 536 |
|
|
2024
Q1 | $33.3M | Sell |
245,995
-5,980
| -2% | -$792K | 0.04% | 555 |
|
|
2023
Q4 | $33.9M | Buy |
251,975
+62
| +0% | +$8.06K | 0.04% | 551 |
|
|
2023
Q3 | $34.1M | Buy |
251,913
+5,859
| +2% | +$800K | 0.04% | 516 |
|
|
2023
Q2 | $35.2M | Sell |
246,054
-9,158
| -4% | -$1.35M | 0.04% | 538 |
|
|
2023
Q1 | $35.4M | Buy |
255,212
+1,410
| +0.6% | +$190K | 0.04% | 530 |
|
|
2022
Q4 | $34.4M | Sell |
253,802
-456
| -0.2% | -$57.2K | 0.04% | 562 |
|
|
2022
Q3 | $27.9M | Sell |
254,258
-18,461
| -7% | -$2.34M | 0.03% | 602 |
|
|
2022
Q2 | $36M | Sell |
272,719
-6,319
| -2% | -$829K | 0.04% | 566 |
|
|
2022
Q1 | $37K | Sell |
279,038
-110,452
| -28% | -$13.2M | 0.03% | 614 |
|
|
2021
Q4 | $45.4M | Sell |
389,490
-18,558
| -5% | -$2.18M | 0.04% | 543 |
|
|
2021
Q3 | $49M | Sell |
408,048
-81,160
| -17% | -$9.45M | 0.04% | 534 |
|
|
2021
Q2 | $58.6M | Buy |
489,208
+433,297
| +775% | +$47.5M | 0.05% | 485 |
|
|
2021
Q1 | $5.56M | Buy |
55,911
+13,125
| +31% | +$1.32M | 0.01% | 884 |
|
|
2020
Q4 | $4.28M | Sell |
42,786
-7,907
| -16% | -$838K | 0.01% | 917 |
|
|
2020
Q3 | $5.56M | Sell |
50,693
-717
| -1% | -$79.7K | 0.01% | 802 |
|
|
2020
Q2 | $5.44M | Buy |
51,410
+10,239
| +25% | +$1.06M | 0.01% | 782 |
|
|
2020
Q1 | $3.68M | Sell |
41,171
-305
| -0.7% | -$28.7K | 0.01% | 780 |
|
|
2019
Q4 | $4.14M | Sell |
41,476
-886
| -2% | -$83.4K | 0.01% | 853 |
|
|
2019
Q3 | $3.78M | Sell |
42,362
-97,050
| -70% | -$8.41M | 0.01% | 831 |
|
|
2019
Q2 | $11.5M | Buy |
139,412
+3,000
| +2% | +$235K | 0.02% | 587 |
|
|
2019
Q1 | $11M | Sell |
136,412
-10,250
| -7% | -$808K | 0.02% | 602 |
|
|
2018
Q4 | $11.1M | Sell |
146,662
-26,450
| -15% | -$2.07M | 0.02% | 576 |
|
|
2018
Q3 | $13.7M | Sell |
173,112
-9,750
| -5% | -$737K | 0.02% | 571 |
|
|
2018
Q2 | $12.8M | Buy |
182,862
+5,850
| +3% | +$421K | 0.02% | 583 |
|
|
2018
Q1 | $12.4M | Sell |
177,012
-78,388
| -31% | -$5.43M | 0.02% | 574 |
|
|
2017
Q4 | $17.7M | Sell |
255,400
-20,350
| -7% | -$1.37M | 0.03% | 500 |
|
|
2017
Q3 | $18.7M | Buy |
275,750
+5,275
| +2% | +$333K | 0.03% | 465 |
|
|
2017
Q2 | $18.4M | Buy |
270,475
+11,800
| +5% | +$771K | 0.03% | 465 |
|
|
2017
Q1 | $16.1M | Buy |
258,675
+16,142
| +7% | +$940K | 0.03% | 502 |
|
|
2016
Q4 | $13.3M | Buy |
242,533
+28,050
| +13% | +$1.59M | 0.03% | 547 |
|
|
2016
Q3 | $14.1M | Buy |
214,483
+75,517
| +54% | +$4.94M | 0.03% | 515 |
|
|
2016
Q2 | $8.39M | Buy |
138,966
+121,966
| +717% | +$7.08M | 0.01% | 759 |
|
|
2016
Q1 | $957K | Buy |
17,000
+640
| +4% | +$38.5K | ﹤0.01% | 1132 |
|
|
2015
Q4 | $1.11M | Sell |
16,360
-350
| -2% | -$22.9K | ﹤0.01% | 1058 |
|
|
2015
Q3 | $1.06M | Buy |
16,710
+988
| +6% | +$65K | ﹤0.01% | 1126 |
|
|
2015
Q2 | $1M | Buy |
15,722
+1,354
| +9% | +$92.7K | ﹤0.01% | 1178 |
|
|
2015
Q1 | $983K | Buy |
14,368
+3,000
| +26% | +$208K | ﹤0.01% | 1159 |
|
|
2014
Q4 | $800K | Hold |
11,368
| – | – | ﹤0.01% | 1201 |
|
|
2014
Q3 | $812K | Buy |
11,368
+500
| +5% | +$36.6K | ﹤0.01% | 1193 |
|
|
2014
Q2 | $808K | Sell |
10,868
-700
| -6% | -$50.6K | ﹤0.01% | 1235 |
|
|
2014
Q1 | $751K | Sell |
11,568
-2,800
| -19% | -$181K | ﹤0.01% | 1211 |
|
|
2013
Q4 | $853K | Sell |
14,368
-400
| -3% | -$21.7K | ﹤0.01% | 1184 |
|
|
2013
Q3 | $767K | Hold |
14,768
| – | – | ﹤0.01% | 1226 |
|
|
2013
Q2 | $699K | Buy |
+14,768
| New | +$752K | ﹤0.01% | 1222 |
|
Other funds holding AZN
EP
IA
Macquarie Group's AZN Position: Q2 2026 in Review
Macquarie Group held its AstraZeneca (AZN) position steady in Q2 2026 at 120,191 shares worth $22.8M. The position accounts for 0.1% of the portfolio, ranked #174.
Macquarie Group first reported a position in AZN in Q2 2013 and has held it in 52 quarters since. The position peaked at $58.6M in Q2 2021. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Macquarie Group held 120,191 shares of AstraZeneca worth $22.8M as of Q2 2026.
- Macquarie Group left its AstraZeneca share count unchanged in Q2 2026.
- AstraZeneca made up 0.1% of Macquarie Group's portfolio in Q2 2026, its #174 holding.
- Macquarie Group first reported a position in AstraZeneca in Q2 2013 and has held it in 52 quarters since.
- Macquarie Group's AstraZeneca position peaked at $58.6M in Q2 2021.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Macquarie Group's 13F filing for Q2 2026, filed 14 Aug 2026.